BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced that the Company has completed implementation of the new MicroThermX ® Microwave Ablation System (MicroThermX ®) direct sales program in major metropolitan areas throughout the U.S. BSD has moved to a direct sales model in order to capitalize on the Company's new rental program, which allows hospitals to purchase disposable antennas and pay a fee-per-use for the treatment of patients using the MicroThermX ®. This new sales model will allow BSD to clearly focus on major areas of opportunity in the ablation market. BSD has hired direct sales representatives to cover the following key metropolitan areas: Florida, New York, New Jersey, Philadelphia, Chicago, Detroit, Phoenix, Las Vegas, Southern California, Dallas and Houston. The Company plans to continue to expand the direct sales program into other metropolitan areas in the future. “We are pleased with the success of the direct sales model for the MicroThermX ®,” said Harold Wolcott, BSD President and CEO. “Our new program has already resulted in over a 100% increase in clinical evaluations scheduled over the next quarter. There has also been a significant increase in requests for purchase and interest in the fee-per-use rental program.” About the MicroThermX ® Microwave Ablation System The MicroThermX ® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX ® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX ® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX ® introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX ® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX ® System, which allows BSD to market the MicroThermX ® in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX ® to a number of international markets. About BSD Medical Corporation BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com. Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.